• PMGC unit NorthStrive Biosciences amended its development and license deal with Yuva Biosciences to expand an AI drug-discovery program.
• Six-month plan advances four validated small-molecule candidates toward lead nomination, targeting cardiac disease and obesity applications.
• Program follows July 1, 2026 Phase III results showing statistically significant ANT1 increases in primary human skeletal muscle cells.
• Amendment reinforces NorthStrive’s exclusive cardiac disease and obesity rights, adding a right of first refusal in broader cardiometabolic indications.
• Expansion work starts with Phase I assay development, with lead and backup selection targeted at the end of Phase III.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609010745PRIMZONEFULLFEED9819327) on September 01, 2026, and is solely responsible for the information contained therein.